Amanote Research
Register
Sign In
Two Case Trials of Neoadjuvant Chemoradiotherapy With TS-1 + Gemcitabine + 50 Gy Radiotherapy in Unresectable (Borderline Resectable) Pancreas Body Cancer
HPB
- United Kingdom
doi 10.1016/j.hpb.2016.03.205
Full Text
Open PDF
Abstract
Available in
full text
Categories
Hepatology
Gastroenterology
Date
April 1, 2016
Authors
S.S. Yun
D.S. Lee
H.J. Kim
Publisher
Elsevier BV
Related search
A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Journal of Carcinogenesis & Mutagenesis
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Journal of Clinical Medicine
Outcomes With FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer
Journal of Surgical Oncology
Medicine
Surgery
Oncology
Significance of Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Head Cancer: Pathological Local Invasion and Microvessel Invasion Analysis
Molecular and Clinical Oncology
Cancer Research
Oncology
Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer
British Journal of Surgery
Surgery
Neoadjuvant Imatinib for Borderline Resectable GIST
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
A Phase I Study of Neoadjuvant Chemotherapy With Gemcitabine Plus Oral S-1 for Resectable Pancreatic Cancer
Molecular and Clinical Oncology
Cancer Research
Oncology
A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Annals of Surgery
Surgery
Optimal Neoadjuvant Radiotherapy Dose for Esophageal Cancer: An NCDB Analysis of 41.4 Gy Versus 50.4 Gy
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
